Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 14Prostatic Neoplasms 3Neoplasms, Hormone-Dependent 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3Prostatic Intraepithelial Neoplasia 2Fractures, Bone 2Desmoid Tumors 2Triple Negative Breast Neoplasms 1Precancerous Conditions 1Ovarian Neoplasms 1Osteoporosis 1Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Carcinoma In Situ 1Breast Cancer Patients in Premenopausal 1Bone Diseases, Metabolic 1

Interventions

Tamoxifen 21Radiotherapy 9Chemotherapy, Adjuvant 9Early Intervention, Educational 8Specimen Handling 7Anastrozole 7Neoadjuvant Therapy 6Methods 6Letrozole 6Practice Guidelines as Topic 5Counseling 5Biopsy 5Standard of Care 4Magnetic Resonance Spectroscopy 4Educational Status 4Behavior Therapy 4exemestane 3Radiation Dose Hypofractionation 3Radiation 3Psychiatric Rehabilitation 3Mastectomy, Segmental 3Brachytherapy 3Therapeutics 2Telemedicine 2Taxes 2Surveys and Questionnaires 2Soybean Proteins 2Simvastatin 2Radiotherapy, Conformal 2Proton Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Carcinoma In Situ × Toremifene × Clear all
NCT03238703 2018-12-27

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Fred Hutchinson Cancer Center

Phase 4 Withdrawn
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡